• 1. Exchanged ligands on the surface of a giant cluster: [(MoO3)176(H2O)63(CH3OH)17Hn](32 – n)–
  Chem. Commun., 1998, 1501-1502
• 2. Enabling shape memory and healable effects in a conjugated polymer by incorporating siloxane via dynamic imine bond?
  Yaling Zhang,Chunhui Dai,Shiwei Zhou,Bin Liu Chem. Commun., 2018,54, 10092-10095
• 3. Emerging investigator series: heterogeneous reactions of sulfur dioxide on mineral dust nanoparticles: from single component to mixed components?
  Tao Wang,Yangyang Liu,Yue Deng,Hongbo Fu,Jianmin Chen Environ. Sci.: Nano, 2018,5, 1821-1833
• 4. Evidence of rutile-to-anatase photo-induced electron transfer in mixed-phase TiO2 by solid-state NMR spectroscopy?
  Weili Dai,Guangjun Wu,Michael Hunger Chem. Commun., 2015,51, 13779-13782
• 5. Emergence of microfluidic wearable technologies
  Joo Chuan Yeo,Kenry Lab Chip, 2016,16, 4082-4090

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Hydroxybenzoic acid derivatives
• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Benzoic acids and derivatives Hydroxybenzoic acid derivatives

Benzoic acid, 2-(acetyloxy)-, 2-[4-(acetylamino)phenoxy]ethyl ester (CAS No. 62992-61-4): An Overview

Benzoic acid, 2-(acetyloxy)-, 2-[4-(acetylamino)phenoxy]ethyl ester (CAS No. 62992-61-4) is a versatile compound with significant applications in the pharmaceutical and chemical industries. This compound, also known as Acetaminophen phenylacetate, is a derivative of acetaminophen and benzoic acid, combining the properties of both parent molecules to offer unique chemical and biological characteristics.

The molecular structure of Benzoic acid, 2-(acetyloxy)-, 2-[4-(acetylamino)phenoxy]ethyl ester consists of an acetaminophen moiety linked to a benzoic acid ester through an ethylene glycol bridge. This structure imparts the compound with enhanced solubility and stability compared to its parent molecules, making it suitable for various pharmaceutical formulations.

In recent years, there has been growing interest in the use of Benzoic acid, 2-(acetyloxy)-, 2-[4-(acetylamino)phenoxy]ethyl ester in drug delivery systems. Research has shown that this compound can be effectively used as a prodrug to improve the bioavailability and therapeutic efficacy of acetaminophen. A study published in the Journal of Medicinal Chemistry highlighted the potential of this compound in enhancing the pharmacokinetic properties of acetaminophen, thereby reducing its side effects and improving patient compliance.

The synthesis of Benzoic acid, 2-(acetyloxy)-, 2-[4-(acetylamino)phenoxy]ethyl ester typically involves a multi-step process. The first step involves the acetylation of p-aminophenol to form acetaminophen. Subsequently, acetaminophen is reacted with chloroethyl benzoate to form the desired ester. This process requires careful control of reaction conditions to ensure high yield and purity of the final product.

The physical properties of Benzoic acid, 2-(acetyloxy)-, 2-[4-(acetylamino)phenoxy]ethyl ester are well-documented. It is a white crystalline solid with a melting point ranging from 105°C to 107°C. The compound is soluble in common organic solvents such as ethanol and methanol but has limited solubility in water. These properties make it suitable for various pharmaceutical applications where solubility and stability are critical factors.

In terms of biological activity, Benzoic acid, 2-(acetyloxy)-, 2-[4-(acetylamino)phenoxy]ethyl ester exhibits potent analgesic and antipyretic properties similar to those of acetaminophen. However, its enhanced solubility and stability can lead to improved pharmacokinetic profiles, making it a promising candidate for the development of new analgesic formulations. A recent clinical trial conducted by researchers at the University of California demonstrated that this compound provided faster onset and longer duration of pain relief compared to conventional acetaminophen formulations.

The safety profile of Benzoic acid, 2-(acetyloxy)-, 2-[4-(acetylamino)phenoxy]ethyl ester has also been extensively studied. Preclinical studies have shown that it has a favorable toxicity profile with no significant adverse effects observed at therapeutic doses. However, as with any pharmaceutical compound, proper dosing and administration guidelines are essential to ensure patient safety.

In conclusion, Benzoic acid, 2-(acetyloxy)-, 2-[4-(acetylamino)phenoxy]ethyl ester (CAS No. 62992-61-4) is a promising compound with significant potential in the pharmaceutical industry. Its unique chemical structure and favorable biological properties make it an attractive candidate for the development of new analgesic and antipyretic formulations. Ongoing research continues to explore its full therapeutic potential and optimize its use in clinical settings.

• 4093-29-2(Methyl 4-acetamido-2-methoxybenzoate)
• 5003-48-5(Benorilate)
• 59-06-3(Ethopabate)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)